These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 35945647)
21. The future of nanomedicine in optimising the treatment of inflammatory bowel disease. Mohan LJ; Daly JS; Ryan BM; Ramtoola Z Scand J Gastroenterol; 2019 Jan; 54(1):18-26. PubMed ID: 30678499 [TBL] [Abstract][Full Text] [Related]
22. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
23. Smart Drug-Delivery Systems for Cancer Nanotherapy. Sanchez-Moreno P; Ortega-Vinuesa JL; Peula-Garcia JM; Marchal JA; Boulaiz H Curr Drug Targets; 2018 Feb; 19(4):339-359. PubMed ID: 27231107 [TBL] [Abstract][Full Text] [Related]
24. Dual and multi-targeted nanoparticles for site-specific brain drug delivery. Luo Y; Yang H; Zhou YF; Hu B J Control Release; 2020 Jan; 317():195-215. PubMed ID: 31794799 [TBL] [Abstract][Full Text] [Related]
25. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362 [TBL] [Abstract][Full Text] [Related]
26. Nanoparticle Delivery Systems for DNA/RNA and their Potential Applications in Nanomedicine. Shen H; Huang X; Min J; Le S; Wang Q; Wang X; Dogan AA; Liu X; Zhang P; Draz MS; Xiao J Curr Top Med Chem; 2019; 19(27):2507-2523. PubMed ID: 31775591 [TBL] [Abstract][Full Text] [Related]
27. Recent advances in combination of microneedles and nanomedicines for lymphatic targeted drug delivery. Permana AD; Nainu F; Moffatt K; Larrañeta E; Donnelly RF Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1690. PubMed ID: 33401339 [TBL] [Abstract][Full Text] [Related]
28. An Overview of Green Synthesis and Potential Pharmaceutical Applications of Nanoparticles as Targeted Drug Delivery System in Biomedicines. Mittal S; Chakole CM; Sharma A; Pandey J; Chauhan MK Drug Res (Stuttg); 2022 Jun; 72(5):274-283. PubMed ID: 35562101 [TBL] [Abstract][Full Text] [Related]
29. Current understandings and clinical translation of nanomedicines for breast cancer therapy. Jiang Y; Jiang Z; Wang M; Ma L Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986 [TBL] [Abstract][Full Text] [Related]
30. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation. Gu W; Meng F; Haag R; Zhong Z J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328 [TBL] [Abstract][Full Text] [Related]
31. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients. Bhattacharjee S; Brayden DJ Expert Opin Drug Discov; 2021 Mar; 16(3):235-254. PubMed ID: 33108229 [TBL] [Abstract][Full Text] [Related]
32. Opening eyes to nanomedicine: Where we are, challenges and expectations on nanotherapy for diabetic retinopathy. Campos EJ; Campos A; Martins J; Ambrósio AF Nanomedicine; 2017 Aug; 13(6):2101-2113. PubMed ID: 28428052 [TBL] [Abstract][Full Text] [Related]
33. Cytopharmaceuticals: An emerging paradigm for drug delivery. Li W; Su Z; Hao M; Ju C; Zhang C J Control Release; 2020 Dec; 328():313-324. PubMed ID: 32889055 [TBL] [Abstract][Full Text] [Related]
34. Nanomedicine Approaches for Advanced Diagnosis and Treatment of Atherosclerosis and Related Ischemic Diseases. Hu B; Boakye-Yiadom KO; Yu W; Yuan ZW; Ho W; Xu X; Zhang XQ Adv Healthc Mater; 2020 Aug; 9(16):e2000336. PubMed ID: 32597562 [TBL] [Abstract][Full Text] [Related]
35. Targeted nanomedicines for the treatment of bone disease and regeneration. Ordikhani F; Zandi N; Mazaheri M; Luther GA; Ghovvati M; Akbarzadeh A; Annabi N Med Res Rev; 2021 May; 41(3):1221-1254. PubMed ID: 33347711 [TBL] [Abstract][Full Text] [Related]
36. Development of Pharmaceutical Nanomedicines: From the Bench to the Market. Halwani AA Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002 [TBL] [Abstract][Full Text] [Related]
37. Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine. Jang SF; Liu WH; Song WS; Chiang KL; Ma HI; Kao CL; Chen MT Int J Mol Sci; 2014 Mar; 15(3):3904-25. PubMed ID: 24599081 [TBL] [Abstract][Full Text] [Related]
38. [Development of Drug Delivery Technology and Nanomedicine by Using Gold Nanoparticles]. Ozeki T; Tagami T Yakugaku Zasshi; 2021; 141(3):323-326. PubMed ID: 33642498 [TBL] [Abstract][Full Text] [Related]
39. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress. Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517 [TBL] [Abstract][Full Text] [Related]
40. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Lembo D; Donalisio M; Civra A; Argenziano M; Cavalli R Expert Opin Drug Deliv; 2018 Jan; 15(1):93-114. PubMed ID: 28749739 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]